Evaluating the Impact of -11.94 Increase on Ocean Biomedical Inc.’s (OCEA) Stock

The stock of Ocean Biomedical Inc. (OCEA) has gone down by -24.34% for the week, with a 58.50% rise in the past month and a 380.30% rise in the past quarter. The volatility ratio for the week is 11.17%, and the volatility levels for the past 30 days are 28.83% for OCEA. The simple moving average for the past 20 days is -26.67% for OCEA’s stock, with a 11.96% simple moving average for the past 200 days.

Is It Worth Investing in Ocean Biomedical Inc. (NASDAQ: OCEA) Right Now?

Moreover, the 36-month beta value for OCEA is 1.31. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for OCEA is 8.57M and currently, short sellers hold a 10.19% of that float. On April 03, 2024, OCEA’s average trading volume was 6.88M shares.

OCEA) stock’s latest price update

Ocean Biomedical Inc. (NASDAQ: OCEA) has experienced a decline in its stock price by -11.94 compared to its previous closing price of 3.60. However, the company has seen a fall of -24.34% in its stock price over the last five trading days. GlobeNewsWire reported 2024-02-29 that Providence, RI, Feb. 29, 2024 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ:  OCEA ), a biopharma company which endeavors to accelerate the development of compelling discoveries from top research scientists, today congratulates its  joint venture partner, Virion Therapeutics, LLC, a clinical-stage biotechnology company developing T cell-based immunotherapies, for the acceptance of their abstract highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure, for late breaker oral presentation at the upcoming 33 rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan from March 27-31, 2024.

OCEA Trading at 43.05% from the 50-Day Moving Average

After a stumble in the market that brought OCEA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.76% of loss for the given period.

Volatility was left at 28.83%, however, over the last 30 days, the volatility rate increased by 11.17%, as shares sank -22.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +459.97% upper at present.

During the last 5 trading sessions, OCEA fell by -24.34%, which changed the moving average for the period of 200-days by -38.92% in comparison to the 20-day moving average, which settled at $4.28. In addition, Ocean Biomedical Inc. saw 380.30% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for OCEA

The total capital return value is set at 1.48. Equity return is now at value -167.94, with -125.17 for asset returns.

Based on Ocean Biomedical Inc. (OCEA), the company’s capital structure generated 3.42 points at debt to capital in total, while cash flow to debt ratio is standing at -0.64. The debt to equity ratio resting at -1.41. The interest coverage ratio of the stock is -3.85.

Currently, EBITDA for the company is -0.96 million with net debt to EBITDA at -0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.08.


To wrap up, the performance of Ocean Biomedical Inc. (OCEA) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts